Cierpicki, Tomasz

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma

Cardenas, M. G., Yu, W., Beguelin, W., Teater, M. R., Geng, H., Goldstein, R. L., Oswald, E., Hatzi, K., Yang, S.-N., Cohen, J., et al. (2016) · Journal of Clinical Investigation

Lymphoma Diagnosis and TreatmentComputational Drug Discovery Methods

Cited by 176

High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction

He, S., Senter, T. J., Pollock, J., Han, C., Upadhyay, S. K., Purohit, T., Gogliotti, R. D., Lindsley, C. W., Cierpicki, T., Stauffer, S. R., et al. (2014) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsComputational Drug Discovery Methods

Cited by 99

Targeting protein–protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?

Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 53